Alpha 2.0
Login Register
» Articles » PMID: 24713845

Systemic Treatment-induced Gastrointestinal Toxicity: Incidence, Clinical Presentation and Management

Overview
Journal Ann Gastroenterol
Specialty Gastroenterology
Date 2014 Apr 10
PMID 24713845
Citations 81
Authors
Stergios Boussios
George Pentheroudakis
Konstantinos Katsanos
Nicholas Pavlidis
Affiliations
Soon will be listed here.
Abstract

The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity during chemotherapy is frequent and contributes to dose reductions, delays and cessation of cancer treatment. The development of intervention strategies that could eliminate an expected side effect of chemotherapy is vital. Physiologic changes that can increase the toxicity of chemotherapy are decreased stem cell reserves, decreased ability to repair cell damage, progressive loss of body protein, and accumulation of body fat. Symptoms only arise when physiological functions are altered. The gastrointestinal symptoms arising during cancer chemotherapy can often be cured if newly acquired, and if gastrointestinal physiological deficits are identified. Developing new chemotherapy regimens with similar efficacy but less toxicity should be a priority for future research.

Citing Articles

Quantitative Fluorescence Imaging of Porphyrin Phospholipid Photobleaching and Light Activated Liposomal Doxorubicin Release Using Wide-field and Laparoscopic SFDI in an Ovarian Cancer Model.

Ahmmed R, Kluiszo E, Aygun-Sunar S, Willadsen M, Kutscher H, Lovell J Res Sq. 2025; .

PMID: 40034443 PMC: 11875292. DOI: 10.21203/rs.3.rs-6030448/v1.

Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity.

Kurian R, Wang H Int J Mol Sci. 2025; 26(3).

PMID: 39940757 PMC: 11816641. DOI: 10.3390/ijms26030988.

The differentiation state of small intestinal organoid models influences prediction of drug-induced toxicity.

Klein J, Heidmann J, Kiyota T, Fullerton A, Homan K, Co J Front Cell Dev Biol. 2025; 13:1508820.

PMID: 39917568 PMC: 11799252. DOI: 10.3389/fcell.2025.1508820.

Integrated Microbiome and Metabolome Analysis Reveals Correlations Between Gut Microbiota Components and Metabolic Profiles in Mice With Mitoxantrone-Induced Cardiotoxicity.

Zhang Q, Liang D, Zhang C, Ye L, Sun P, Zhu H Drug Des Devel Ther. 2025; 19:439-455.

PMID: 39867867 PMC: 11766154. DOI: 10.2147/DDDT.S479682.

Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.

Parvin N, Joo S, Mandal T J Funct Biomater. 2025; 16(1).

PMID: 39852580 PMC: 11766201. DOI: 10.3390/jfb16010024.

References
1.
Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V . Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11):3-10. View
2.
Markman M, Zanotti K, Webster K, Belinson J, Rose P . Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis. Oncology (Williston Park). 2003; 17(5 Suppl 5):34-5. View
3.
De Vita V, Carbone P, OWENS Jr A, GOLD G, KRANT M, Edmonson J . Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res. 1965; 25(11):1876-81. View
4.
Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J . Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004; 113(12):1774-83. PMC: 420505. DOI: 10.1172/JCI20513. View
5.
Dhalluin-Venier V, Besson C, Dimet S, Thirot-Bibault A, Tchernia G, Buffet C . Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2006; 18(11):1235-7. DOI: 10.1097/01.meg.0000243867.56454.13. View